Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

(KRON) — Biotech firm Genentech is laying off nearly 100 employees at its South San Francisco headquarters, according to a WARN notice from the California Employment Development Department (EDD).

She has spent more than 30 years in biopharma circles, including five years as treasurer at Genentech. Kathleen Sereda Glaub, a longtime Bay Area biotech executive who took two companies to ...

Biotech hedge fund investors are much smarter ... Furthermore, as firms like Genentech (now Roche; Basel), Imclone (now Eli Lilly, Indianapolis) and Wyeth (now Pfizer; New York) are acquired ...

With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and ...

Hello! Hope you had a restful and reflective Indigenous Peoples’ Day. Today, we talk about how the autoimmune disease space is hotter than ever, see more gene therapy contraction, and the CEO of ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

Boyer was on the Genentech board of directors but deliberately ... asked Ptashne if he would be interested in starting a biotech company in which the university would have an equity position.

Biotech veteran Kathleen Sereda Glaub ... Glaub was treasurer at South San Francisco-based Genentech Inc. for five years until 1990 and CFO at Cell Genesys before spending 12 years at Plexxikon ...